Recurrent uterine corpus carcinoma Trials in Chicago, United States
Conditions / Recurrent uterine corpus carcinoma / Chicago, United States
Recurrent uterine corpus carcinoma has been the subject of sustained clinical investigation across multiple research sites.
14 total trials for this combination
Showing top 10 of 14 trials
Trials
| NCT ID | Title | Status | Phase |
|---|---|---|---|
| NCT02065687 | Paclitaxel and Carboplatin With or Without Metformin Hydrochloride in Treating Patients With Stage III, IV, or Recurrent Endometrial Cancer | UNKNOWN | PHASE2/PHASE3 |
| NCT01132820 | Cediranib Maleate in Treating Patients With Recurrent or Persistent Endometrial Cancer | COMPLETED | PHASE2 |
| NCT01642082 | Dalantercept in Treating Patients With Recurrent or Persistent Endometrial Cancer | COMPLETED | PHASE2 |
| NCT01011933 | Selumetinib in Treating Patients With Recurrent or Persistent Endometrial Cancer | COMPLETED | PHASE2 |
| NCT01225887 | Nintedanib in Treating Patients With Recurrent or Persistent Endometrial Cancer | COMPLETED | PHASE2 |
| NCT00478426 | Sunitinib Malate in Treating Patients With Recurrent or Metastatic Endometrial Cancer | COMPLETED | PHASE2 |
| NCT00729586 | Temsirolimus With or Without Megestrol Acetate and Tamoxifen Citrate in Treating Patients With Advanced, Persistent, or Recurrent Endometrial Cancer | COMPLETED | PHASE2 |
| NCT00063999 | Doxorubicin Hydrochloride, Cisplatin, and Paclitaxel or Carboplatin and Paclitaxel in Treating Patients With Stage III-IV or Recurrent Endometrial Cancer | COMPLETED | PHASE3 |
| NCT00897442 | Collecting Tumor Samples From Patients With Gynecological Tumors | COMPLETED | — |
| NCT01010126 | Temsirolimus and Bevacizumab in Treating Patients With Advanced Endometrial, Ovarian, Liver, Carcinoid, or Islet Cell Cancer | COMPLETED | PHASE2 |